Trial Profile
An efficacy and safety study comparing pegylated-interferon [peginterferon] and ribavirin plus metformin to pegylated-interferon and ribavirin in the treatment of naive patients with genotype 1 chronic HCV [hepatitis C virus] infection and insulin resistance.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Metformin (Primary) ; Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C; Insulin resistance
- Focus Therapeutic Use
- 16 Oct 2006 New trial record.